Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Plasma cell leukaemia and other aggressive plasma cell malignancies.

Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A.

Br J Haematol. 2010 Aug;150(4):418-27. doi: 10.1111/j.1365-2141.2010.08157.x. Review.

2.

Plasma cell leukemia: concepts and management.

Liedtke M, Medeiros BC.

Expert Rev Hematol. 2010 Oct;3(5):543-9. doi: 10.1586/ehm.10.52. Review.

PMID:
21083471
3.

[Plasma cell leukemia].

Ravinet A, Bay JO, Tournilhac O.

Bull Cancer. 2014 Nov;101(11):1048-58. doi: 10.1684/bdc.2014.2048. Review. French.

PMID:
25418598
4.

Efficacy and safety of bortezomib in patients with plasma cell leukemia.

Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R, Palumbo A; GISMM Cooperative Group; GISL Cooperative Group; GIMEMA Cooperative Group.

Cancer. 2007 Jun 1;109(11):2285-90.

5.

Bortezomib: an effective agent in extramedullary disease in multiple myeloma.

Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E.

Eur J Haematol. 2006 May;76(5):405-8. Epub 2006 Mar 9.

PMID:
16529604
6.

Novel therapies in the treatment of multiple myeloma.

Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.

J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.

PMID:
19878638
7.

Multiple myeloma.

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.

Lancet. 2009 Jul 25;374(9686):324-39. doi: 10.1016/S0140-6736(09)60221-X. Epub 2009 Jun 21. Review.

PMID:
19541364
8.

Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.

Ueda S, Kubo M, Matsuura N, Matsunaga H, Kataoka S, Maeda T, Inui Y, Kawata S, Kanakura Y.

Intern Med. 2013;52(11):1235-8. Review.

9.

The use of novel agents in the treatment of relapsed and refractory multiple myeloma.

Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.

Leukemia. 2009 Dec;23(12):2222-32. doi: 10.1038/leu.2009.179. Epub 2009 Sep 10. Review.

10.

Multiple myeloma.

Laubach J, Richardson P, Anderson K.

Annu Rev Med. 2011;62:249-64. doi: 10.1146/annurev-med-070209-175325. Review.

PMID:
21090965
11.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83. Review.

PMID:
21322778
12.

Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.

Minarik J, Scudla V, Bacovsky J, Zemanova M, Pika T, Ordeltova M, Langova K.

Neoplasma. 2010;57(1):8-14.

PMID:
19895166
13.

The treatment of relapsed and refractory multiple myeloma.

Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K.

Hematology Am Soc Hematol Educ Program. 2007:317-23. Review.

PMID:
18024646
14.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
15.

Treatment of newly diagnosed multiple myeloma.

Palumbo A, Magarotto V, Larocca A, Bringhen S, Falco P, Di Raimondo F, Baldini L, Boccadoro M.

Curr Hematol Malig Rep. 2008 Apr;3(2):107-14. doi: 10.1007/s11899-008-0016-8.

PMID:
20425454
16.

Clinical management of myeloma--state of the art.

Harousseau JL.

Cancer Treat Rev. 2010 May;36 Suppl 2:S1-2. doi: 10.1016/S0305-7372(10)00081-2.

PMID:
20472182
17.

Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.

Ito C, Aisa Y, Mihara A, Nakazato T.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):83-5. doi: 10.1016/j.clml.2012.08.005. Epub 2012 Oct 25. No abstract available.

PMID:
23103083
18.

New therapies in multiple myeloma.

Merchionne F, Perosa F, Dammacco F.

Clin Exp Med. 2007 Sep;7(3):83-97. Epub 2007 Oct 3. Review.

19.

Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.

Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. Epub 2013 Jan 4.

PMID:
23291040
20.

Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.

Bruce JT, Tran JM, Phillips G, Elder P, Mastronarde JG, Devine SM, Hofmeister CC, Wood KL.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):325-9. doi: 10.1016/j.clml.2012.06.002. Epub 2012 Sep 15.

Supplemental Content

Support Center